期刊
ACS CHEMICAL BIOLOGY
卷 8, 期 11, 页码 2577-2585出版社
AMER CHEMICAL SOC
DOI: 10.1021/cb4002602
关键词
-
资金
- National Medical Research Council [NMRC/1260/2010]
- Ministry of Education of Singapore [MOE2012-T2-1-116]
- Singapore-Peking-Oxford Research Enterprise [COY-15-EWI-RCFSA/N197-1]
Proper folding of cellular proteins is assisted by protein disulfide isomerases (PDIs) in the endoplasmic reticulum of mammalian cells. Of the at least 21 PDI family members known in humans, the 57-kDa PDI has been found to be a potential therapeutic target for a variety of human diseases including cancer and neurodegenerative diseases. Consequently, small molecule PDI-targeting inhibitors have been actively pursued in recent years, and thus far, compounds possessing moderate inhibitory activities (IC50 between 0.1 and 100 mu M against recombinant PDI) have been discovered. In this article, by using in situ proteome profiling experiments in combination with in vitro PDI enzymatic inhibition assays, we have discovered a phenyl vinyl sulfonate-containing small molecule (P1; shown) as a relatively potent and specific inhibitor of endogenous human PDI in several mammalian cancer cells (e.g., GI(50) similar to 4 mu M). It also possesses an IC50 value of 1.7 +/- 0.4 mu M in an in vitro insulin aggregation assay. Our results indicate P1 is indeed a novel, cell-permeable small molecule PDI inhibitor, and the electrophilic vinyl sulfonate scaffold might serve as a starting point for future development of next-generation PDI inhibitors and probes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据